文献速递甲状腺疾病

APLP2、RRM2和PRC1:甲状腺滤泡性病变鉴别诊断的新候选标志物

APLP2, RRM2, and PRC1: New Putative Markers for the Differential Diagnosis of Thyroid Follicular Lesions.
PubMed 文献 · Thyroid · 2016-11-30

本回顾性分析评估19种蛋白在81例良性甲状腺病变(FA)和50例恶性肿瘤(FTC/FVPTC)中的免疫表达,构建基于APLP2、RRM2和PRC1的评分模型,在主组和验证组中鉴别良恶性病变的敏感性均为100%,特异性分别为71.3%和50.7%。

要点

  • 基于APLP2、RRM2和PRC1的评分模型在主组和验证组中鉴别良恶性病变的敏感性均为100%。
  • 该模型在主组和验证组中的特异性分别为71.3%和50.7%,在结节性增生组中特异性达94.8%。
  • 在FNAB细胞块样本中,该模型鉴别良恶性病变的敏感性为100%,特异性为45%。

核心结论

  • 研究提示APLP2、RRM2和PRC1标志物组合可能有助于区分甲状腺滤泡上皮的良性(FA)与恶性(FTC和FVPTC)肿瘤。

研究设计与样本

  • 回顾性分析,评估19种蛋白在81例良性甲状腺病变(FA)和50例恶性肿瘤(FTC/FVPTC)中的免疫表达。
  • 模型验证使用独立系列69例FA和40例FTC,以及外部系列40例结节性增生,并在38例FNAB细胞块中进一步测试。

主要发现

  • 基于APLP2、RRM2和PRC1核表达与胞质表达的模型在主组和验证组中鉴别良恶性病变的敏感性均为100%,特异性分别为71.3%和50.7%。
  • 在结节性增生系列中,该模型特异性达94.8%。
  • 在FNAB样本中,该模型鉴别良恶性病变的敏感性为100%,特异性为45%。

关键数值与推荐

  • 模型基于APLP2、RRM2和PRC1的核表达与胞质表达进行评分。
  • 主组敏感性100%,特异性71.3%;验证组敏感性100%,特异性50.7%。
  • 结节性增生系列特异性94.8%;FNAB样本敏感性100%,特异性45%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Current methods based on fine-needle aspiration biopsy (FNAB) are not sufficient to distinguish among follicular thyroid lesions, follicular adenoma (FA), follicular thyroid carcinoma (FTC), and the follicular variant of papillary thyroid cancer (FVPTC). Furthermore, none of the immunohistochemical markers currently available are sensitive or specific enough to be used in the clinical setting, necessitating a diagnostic hemithyroidectomy. The aim of this study was to identify proteins of value for differential diagnosis between benign and malignant thyroid follicular lesions. METHODS: This retrospective analysis is based on an assessment of the immunoexpression of 19 proteins on 81 benign thyroid lesions (FA) and 50 malignant tumors (FTC/FVPTC). The resulting expression profile allowed the design of a scoring system model to improve the differential diagnosis of benign and malignant thyroid lesions. The model was validated using an independent series of 69 FA and 40 FTC and an external series of 40 nodular hyperplasias, and was further tested in a series of 38 FNAB cell blocks. RESULTS: A model based on the nuclear and cytoplasmic expression of APLP2, RRM2, and PRC1 discriminated between benign and malignant lesions with 100% sensitivity in both main and validation groups, with specificities of 71.3% and 50.7%, respectively. For the nodular hyperplasia series, specificity reached 94.8%. Finally, in FNAB samples, the sensitivity was 100% and the specificity was 45% for discrimination between benign and malignant lesions. CONCLUSIONS: These findings suggest that the identified APLP2, RRM2, and PRC1 signature could be useful for distinguishing between benign (FA) and malignant (FTC and FVPTC) tumors of the thyroid follicular epithelium.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Castelblanco E, Zafon C, Maravall J, et al. APLP2, RRM2, and PRC1: New Putative Markers for the Differential Diagnosis of Thyroid Follicular Lesions. Thyroid. 2016. PMID: 27796194. doi:10.1089/thy.2016.0094

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。